Ondine Biomedical, Inc. (GB:OBI) has released an update.
Ondine Biomedical Inc.’s innovative Steriwave technology is set for a pilot at King’s College Hospital, aiming to combat hospital-acquired infections with its light-activated antimicrobial treatment. This technology has already been adopted by Mid Yorkshire Teaching NHS Trust for surgical site infection prevention, and its recent inclusion in the NHS Supply Chain enhances accessibility across England and Wales. Steriwave’s unique approach rapidly eliminates pathogens, offering a promising alternative to antibiotics without the risk of resistance.
For further insights into GB:OBI stock, check out TipRanks’ Stock Analysis page.
